BACKGROUND: New-generation bare-metal nitinol (BNS) and drugeluting stents have improved long-term outcomes in patients undergoing endovascular therapy for femoropopliteal lesions. Furthermore, cilostazol reduces in-stent restenosis (ISR) after first-generation BNS implantation for femoropopliteal lesions.
F
emoropopliteal lesions are present in 60% to 70% of patients with symptomatic peripheral artery disease. [1] [2] [3] During the era of first-generation baremetal nitinol stents (BNS), the yearly incidence of restenosis was 20% to 50%. [4] [5] [6] A new-generation BNS, the Misago stent, showed a 1-year primary patency of 82.9%, owing to their high flexibility, which led to a lower fracture rate. 7 Iida et al 8 reported that cilostazol reduced the in-stent restenosis (ISR) rate by almost half after using first-generation BNS for femoropopliteal lesions. In real-world daily practice of endovascular therapy (EVT) for femoropopliteal lesions, we have adopted 3 different approaches to stenting: BNS without cilostazol, BNS with cilostazol, and drug-eluting stents (DES). However, to this day, even with the introduction of new-generation BNS, the effectivity of cilostazol in reducing ISR is unclear. Additionally, it is not known whether new-generation BNS with cilostazol or DES is more effective in reducing ISR after EVT for femoropopliteal lesions. To address this daily clinical question, the DEBATE in SFA (Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in Treatment of Superficial Femoral Artery) randomized clinical trial was designed to clarify which among the 3 strategies is the most effective in reducing the 1-year ISR rate after EVT for femoropopliteal.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Design
This was a prospective, randomized, open-label, multicenter study. Between March 2014 and April 2016, 255 patients with symptomatic peripheral artery disease because of de novo femoropopliteal lesions were enrolled from 25 cardiovascular centers and randomized. Written informed consent was obtained from all patients. The present study was approved by each of the hospitals' ethics committees and was performed in accordance with the Declaration of Helsinki.
Participants
All patients with peripheral artery disease and symptomatic claudication or rest pain (Rutherford 2-4) who had de novo femoropopliteal lesions who were referred to the outpatient clinic at the participating hospitals were potentially eligible. Patients receiving dual antiplatelet therapy after coronary DES implantation, unable to receive cilostazol because of severe heart failure, with femoropopliteal lesion with inflow aortoiliac lesions, with poor below-the-knee runoff, defined as <1 below-the-knee runoff, receiving anticoagulant drugs, with bleeding tendency, or with acute or subacute limb ischemia were excluded.
Randomization
Eligible patients were assigned in a 1:1:1 ratio of treatment with Misago stent without cilostazol (BNS group), Misago stent with cilostazol (BNS with cilostazol group), or Zilver PTX stent without cilostazol (DES group). Randomization was done centrally using a computer algorithm. After randomization, the patients in the BNS group received aspirin, 100 mg/d, for 12 months and clopidogrel, 75 mg/d, for 1 month; those in the BNS with cilostazol group received aspirin, 100 mg/d, and cilostazol, 200 mg/d, for 12 months; and those in the DES group received aspirin, 100 mg/d, and clopidogrel, 75 mg/d, for 12 months.
Endovascular Procedure and Lesion Measurement
The decision on the approach site was left at the discretion of the physicians. In almost all cases, a 6-French sheath was inserted into the femoral artery via the contralateral or ipsilateral approach. After 3000 to 5000 U of heparin infusion, the lesion was crossed with a 0.014-or 0.035-inch guidewire. The lesion was dilated with a noncompliant or scoring balloon whose size was 1 mm smaller than the diameter of the distal vessel before stent implantation. After implanting a stent with a diameter 1 mm larger than the reference vessel, postdilatation was performed with a noncompliant balloon whose size was equivalent to the diameter of the distal vessel. The decision on use of intravascular ultrasonography was left at the discretion of the physicians.
The proximal and distal reference vessels and lesion length were measured from angiographic data.
Outcomes Assessment
Outcomes assessment was performed at the 1-, 3-, 6-, and 12-month follow-up visits to assess for symptoms,
WHAT IS KNOWN
• Insufficient patency after stenting remains a limitation of endovascular therapy for femoropopliteal lesions.
• Cilostazol reduces in-stent restenosis after firstgeneration bare-metal nitinol (BNS) implantation for femoropopliteal lesions.
• Drug-eluting stents is superior to BNS in reducing in-stent restenosis.
WHAT THE STUDY ADDS
• drug compliance, the ankle-brachial index, and the presence of restenosis using duplex ultrasound. Baseline medical history and demographic data, including age and sex, were obtained from the patients' report to allow external generalizability of the study results. Blood examination data, weight, and height were measured at the study visit. The primary measure was 1-year restenosis noted using duplex ultrasound (peak systolic velocity ratio, >2.0). All stent lengths were assessed whether 1 or multiple stents were placed. The secondary measure was major adverse limb events, defined as composite of limb-related death, target lesion revascularization, major amputation, major bleeding, and definite or probable stent thrombosis. ISR was classified into 3 types based on the classification of Tosaka et al 9 : class I, focal lesions (length, 50 mm); class II, diffuse lesions (length, >50 mm); and class III, totally occluded ISR.
Statistical Analysis
The sample size was estimated based on the binary restenosis rates from previous trials. An overall sample size of 270 patients was expected to have 80% power to detect a difference in 1-year ISR after Misago stenting with cilostazol compared with that without cilostazol at a 2-sided α of 0.05, assuming a binary restenosis rate of 20% in the BNS with cilostazol group and 50% in the BNS without cilostazol group. Data are shown as mean±SD for continuous variables or as percentages for dichotomous variables, unless specified otherwise. P<0.05 was considered statistically significant. Baseline medical history and demographic data in the 3 groups were compared using the correction for multiple testing. All results were based on an intention-totreat analysis. For the primary outcome measure, life-table analysis using fixed time points of observation was performed to assess the differences in primary patency among the 3 groups. Statistical analyses were performed using SPSS version 24 (IBM Corp, Armonk, NY).
RESULTS
A total of 255 patients were randomly assigned to the BNS (n=85), BNS with cilostazol (n=85), or DES groups (n=85; Figure 1 ). The 3 groups were well matched at baseline in terms of demographic data (Table 1 ) and lesion characteristics ( Table 2 ). The median length of the treated segment was 100 mm (interquartile range, 46.7-190.0 mm), and 42% were chronic total occlusion lesions. Importantly, the frequency of involvement of the proximal SFA or popliteal artery was similar among the 3 groups. Because 2 patients had failed EVT, the remaining 253 patients were analyzed in the intention-to-treat analysis. During the 1-year followup, 12 (4.7%) patients died (1, 5, and 5 in the BNS, BNS with cilostazol, and DES groups, respectively) and 237 (92.9%) had relevant ultrasound findings. In the BNS with cilostazol group, 6 (7.1%) patients had their cilostazol doses reduced or discontinued (2 reduced their doses from 200 to 100 mg/d because of palpitation and edema and 4 discontinued cilostazol because of palpitation and allergy). The 1-year ISR rate did not differ significantly among the BNS, BNS with cilostazol, and DES groups (28.4% versus 12.2% versus 21.0%, P=0.052; Figure 2 ). Although the 1-year ISR was similar between the BNS with cilostazol and DES groups (P=0.16), it was significantly lower in the BNS with cilostazol group than in the BNS group (P=0.018). Major adverse limb event was significantly higher in the BNS group (16.9% versus 6.5% versus 6.3%; P=0.034); however, target lesion revascularization and major bleeding were similar (Table 3 ). In terms of safety measures, probable stent thrombosis occurred in 4 cases (3, 0, and 1 in the BNS, BNS with cilostazol, and DES group, respectively; P=0.17). In the subgroup analysis of patients with small vessels (<5 mm), the Kaplan-Meier analysis showed that the BNS with cilostazol group tended to have lower ISR rate than the other 2 groups (BNS versus BNS with cilostazol, 24.3% versus 9.3%, P=0.066; BNS with cilostazol versus DES, 9.3% versus 23.5%, P=0.084; Figure3A).
Furthermore, in the TASC II (Trans-Atlantic Inter-Society Consensus II) C/D lesions, the BNS with cilostazol group had a significantly lower ISR rate than the BNS group (9.4% versus 50.9%; P<0.001) but had a similar rate to the DES group (9.4% versus 21.2%; P=0.21; Figure 3B ).
Comparison of Effectiveness in Reducing ISR Between the DES and BNS With Cilostazol Groups
The frequency of 1-year ISR was similar between the DES and BNS with cilostazol groups. Subgroup Cox proportional analysis showed no significant treatment-by-subgroup interaction for all subgroups, and there was no significant difference between the 2 groups except in the presence of diabetes mellitus. However, almost all subgroups received greater 
Data are shown as the mean±SD, median (interquartile range), or n (percentages). ABI indicates ankle-brachial index; ACE-I, angiotensinconverting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BNS, bare-metal nitinol stents; CAD, coronary artery disease; DES, drugeluting stents; eGFR, estimated glomerular filtration rate; IVUS, intravascular ultrasonography; and LV, left ventricular.
benefit from BNS with cilostazol than from DES ( Figure 4) .
Comparison of ISR Types
Tosaka class I occurred in 10 (44%; BNS), 8 (89%; BNS with cilostazol), and 10 (62%; DES) patients; Tosaka class II occurred in 7 (30%; BNS), 0 (0%; BNS with cilostazol), and 3 (19%; DES) patients; and Tosaka class III occurred in 6 (26%; BNS), 1 (11%; BNS with cilostazol), and 3 (19%; DES) patients. Overall analysis showed that the distribution of ISR type was significantly different among the 3 groups (P=0.048; Figure 5 ).
ISR Defined as Peak Systolic Velocity Ratio >2.4
Some reports defined ISR as peak systolic velocity ratio >2.4, which we used in the life- 
DISCUSSION
The DEBATE in SFA study is a prospective, randomized, multicenter study designed to investigate whether cilostazol is effective in reducing ISR after implantation of new-generation BNS implantation and to determine whether new-generation BNS with cilostazol or DES are superior in reducing ISR after EVT for femoropopliteal lesions.
To the best of our knowledge, the DEBATE in SFA study is the first to reveal that (1) cilostazol significantly reduces ISR in second-generation BNS at 1 year, (2) almost 90% patients with ISR had class I (ie, focal) type in the BNS with cilostazol group, and (3) in patients Data are shown as the mean±SD, median (interquartile range), n (percentages), or number per group (n/n/n). BNS indicates bare-metal nitinol stents; CTO, chronic total occlusion; DES, drug-eluting stents; P1, popliteal 1; SFA, superficial femoral artery; and TASC, Trans-Atlantic Inter-Society Consensus. with TASC C/D femoropopliteal lesions, second-generation BNS with cilostazol and DES were more effective in reducing 1-year ISR than BNS without cilostazol.
The STOP-IC study (Sufficient Treatment of Peripheral Intervention by Cilostazol) showed that cilostazol remarkably reduced ISR, as detected by angiography, after firstgeneration BNS implantation for femoropopliteal lesions (BNS versus BNS with cilostazol, 49% versus 20%; P=0.0001). Patients in the STOP-IC study had a mean lesion length of almost 130 mm and mean reference vessel diameter of 5.4 mm; 40% had chronic total occlusions, and 40% had TASC C/D. Our study also revealed a similar trend in second-generation BNS. However, the ISR rate was lower in our study compared with that in the STOP-IC. One of the reasons was the higher intravascular ultrasonography usage rate in our study. Because the final vessel diameter on intravascular ultrasonography is strongly associated with long-term patency, 1 reason for the discrepant rates may be that our study population had relatively shorter lesions and higher intravascular ultrasonography usage rates than the STOP-IC patients. 8 Zilver PTX is effective for reducing ISR within 5 years after EVT compared with the Zilver flex bare stent. 10 The current study revealed similar trends between Zilver PTX and second-generation BNS without cilostazol groups. However, the question of whether new-generation BNS with cilostazol is more effective in reducing ISR after EVT for femoropopliteal lesions than does DES remains unresolved. Our study showed that second-generation BNS with cilostazol and DES significantly reduced ISR after EVT for femoropopliteal lesions compared with second-generation BNS without cilostazol. Furthermore, second-generation BNS with cilostazol was sometimes superior to DES in reducing ISR after EVT for femoropopliteal lesions, such as in patients with small lesions. The ZEPHYR study (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery) showed that Zilver PTX was not effective in reducing ISR for femoropopliteal lesions with a distal elastic membrane area ≤27 mm 2 , minimum stent area ≤12 mm 2 , or length ≥16 cm. 11 Therefore, using BNS with cilostazol, rather than Zilver PTX, might be preferable for small vessel lesions.
However, the adverse effects of cilostazol precluded some patients from benefiting from it. Therefore, confirming the patient's tolerance to cilostazol is an important step before performing EVT for SFA lesions.
In the current study, there was remarkable difference between the ISR and target lesion revascularization rates. One of the reasons was that the definition of ISR (peak systolic velocity ratio >2.0) was too strict to affect the symptom in patients with ISR. In the analysis with ISR defined as peak systolic velocity ratio >2.4. Despite the relatively lower ISR rate, there were significant differences among the 3 groups in overall, small vessels, and TASC II C/D lesions. Using the ISR definition of PSR >2.4 might affect symptoms better than peak systolic velocity ratio >2.0.
Cilostazol Is Good at Reducing ISR for Small Vessels and Long Lesions
In patients with femoropopliteal lesions, small vessels and long lesions are the most challenging lesion in terms of EVT. For small vessels (<4.0 mm), a previous report showed that balloon angioplasty was superior to BNS stenting in terms of 3-year patency by retrospective analysis. 12 Furthermore, drug-coated balloons were more effective than balloon angioplasty for reducing restenosis, especially for diabetic or female patients. 13 It might mean that drug-coated balloons are the best in reducing restenosis in small vessels. However, not all lesions can be treated by drug-coated balloons alone, owing to flow limit dissection after balloon dilatation. Our study revealed that BNS with cilostazol was relatively superior to DES in reducing restenosis in small vessels. Therefore, we recommend BNS with cilostazol when using metal stents.
Soga et al 14 reported that in femoropopliteal lesions, primary patency after EVT with BNS decreased linearly with longer lesion length, but Zeller et al 15 reported that long lesions were suitable for heparin-bonded stent graft (Viabahn) because the 1-year primary patency after EVT with Viabahn was 67%. However, our study revealed that the 1-year primary patency after EVT with BNS with Participants in groups 1, 2, and 3 were assigned to BNS, BNS with cilostazol, and DES treatment, respectively. MALE is defined as a composite of limb-related death, target lesion revascularization, major amputation, and major bleeding. BNS indicates bare-metal nitinol stents; CTO, chronic total occlusion; DES, drug-eluting stents; MALE, major adverse limb event; and TLR, target lesion revascularization.
cilostazol and DES was 90.6% and 78.8%, respectively. Based on our data, DES and especially BNS with cilostazol might be useful in the treatment of TASC II C/D lesions.
ISR Pattern of Each Group
Tosaka et al 9 reported that in BNS patients, class I, II, and II patterns were found in 29%, 38%, and 33%, respectively, 9 whereas Iida et al 16 reported that in DES patients, class I, II, and III patterns were found in 50%, 25%, and 25%, respectively. Our study revealed that cilostazol reduced class II and III ISR in patients with BNS, compared with the BNS without cilostazol and DES groups ( Figure 5 ). Type III ISR had a higher risk of recurrent ISR, especially occlusion after balloon angioplasty. It might mean that cilostazol not only reduced ISR but also rendered femoropopliteal by EVT easier to treat.
Mechanism of Cilostazol's Effect
Cilostazol is well known for improving walking distance in patients with intermittent claudication. Furthermore, There was no significant difference among the 3 groups. However, the bare nitinol stent (BNS) with cilostazol group had a relatively lower ISR rate than the other 2 groups (BNS vs BNS with cilostazol: 24.3% vs 9.3%; P=0.066; BNS with cilostazol vs drug-eluting stent (DES): 9.3% vs 23.5%; P=0.088). B, Patients with Trans-Atlantic Inter-Society Consensus C/D lesions. There was a significant difference among the 3 groups. The BNS with cilostazol group had a significantly lower ISR rate than the BNS group (9.4% vs 50.9%; P<0.001) but had a similar rate to the DES group (9.4% vs 21.2%; P=0.21). The DES group had a significantly lower ISR rate than the BNS group (21.2% vs 50.9%; P=0.002). 17 showed that cilostazol increased blood flow in the resting leg by enhancing the skin perfusion pressure. Cilostazol might reduce ISR through its vasodilatory properties, which may lead to increased blood flow, suppression of neointimal hyperplasia because of its anti-inflammatory effect, improvement of vascular endothelial function, and inhibition of vascular smooth muscle cell proliferation.
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Optimal Antiplatelet Therapy After Stenting for Femoropopliteal Lesion
Zilver PTX was recommended with at least 2-month thienopyridine and life-long aspirin intake after stent implantation to prevent acute stent occlusion by the attached document. Furthermore, expert opinion recommends 1-year dual antiplatelet therapy because of their delayed vascular healing after Zilver PTX implantation. 22 Meanwhile, BNS was generally recommended with at least 1-month dual antiplatelet therapy (aspirin or thienopyridines or cilostazol) after stent implantation to prevent acute stent occlusion for their early stable intimal hyperplasia. 23 Therefore, the antiplatelet therapy regimen of our study was similar to those of real-world daily practice. In our study, the frequency of stent thrombosis was relatively higher in the BNS group than in the BNS with cilostazol and DES groups. It might mean that longer dual antiplatelet therapy use reduces stent thrombosis.
Limitations
Although our study was not double-blinded, the duplex ultrasound scans were examined in a blinded manner. Although all examiners participated in a conference on restenosis assessment before starting this study, evaluation differed between sites. Furthermore, although we had no independent core laboratory to assess initial procedure, our colleagues assessed all angiographic data. Although we used Zilver PTX as the DES in the current study, newer models are available in Europe and other countries other than Japan. Furthermore, the investigation of cilostazol's effects should be expanded to studies using other devices, such as drug-coated balloons and atherectomy devices.
The sample size of our study was calculated with the expectation of detecting a difference between BNS with and without cilostazol. Therefore, although a larger sample size might reveal the significant difference of 1-year primary patency between the BNS with cilostazol and DES groups, we could not show them. Our study could not reveal whether there is an added benefit to cilostazol with DES in terms of reducing ISR. In terms of the study design, although a 4-arm study would have yielded interesting results, triple antiplatelet therapy may cause increased bleeding. Therefore, we designed the study with only 3 arms.
A total of 255 patients were enrolled from 25 cardiovascular centers. There was some bias in the treatment results. Therefore, we showed the enrollment number in each site, which resulted in a large number of study sites (Figures I and II in the Data Supplement).
Although stent fracture was one of the reasons for ISR, we could not collect those data completely. Therefore, we could not provide description about stent fracture.
Conclusions
Second-generation BNS with cilostazol showed a 1-year ISR rate comparable with DES. In some cases, secondgeneration BNS with cilostazol was more effective than DES in reducing ISR rates for femoropopliteal lesions, especially in patients with small vessel disease. Cilostazol reduced the 1-year ISR rate after EVT when used with second-generation BNS for femoropopliteal lesions.
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